Anti-HER2-CAR-T Cells Therapy(First Song Therapeutics)

N/A

Report date: 2024/10/30 17:12:33

Base Information

Drug NameAnti-HER2-CAR-T Cells Therapy(First Song Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-HER2T lymphocyte replacements
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Medical University, ChinaShanghai First Song Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai First Song Therapeutics Co LtdChina Medical University, China
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A